What CE certification means under the EU MDR
CE certification for medical devices is the process of showing that a device meets the applicable European Union requirements before it is placed on the EU market. Under Regulation (EU) 2017/745, known as the Medical Device Regulation or MDR, the manufacturer remains responsible for conformity, technical documentation, clinical evaluation, post-market surveillance and the EU declaration of conformity. For many medium- and high-risk devices, an independent notified body must review the quality management system and technical evidence before the manufacturer can affix the CE marking. For lower-risk Class I devices, the manufacturer may be able to self-declare conformity, unless specific device features trigger notified body involvement.
The CE mark is not a general quality award, a marketing badge or a one-time registration number. It is a legal indication that the manufacturer has followed the applicable conformity assessment route and accepts ongoing obligations under EU law. The MDR applies from 26 May 2021 and replaced the earlier Medical Device Directive and Active Implantable Medical Device Directive for most practical purposes. Readers can follow broader updates in the Regulatory section.
CE mark, CE certificate and declaration of conformity are not the same
The phrase “CE certification” often causes confusion. In day-to-day industry use, it may refer to the whole EU market-access process. Legally, several documents and actions sit within that process, and they do not have the same function.
- CE marking is the symbol placed on the device, packaging or instructions where required after conformity has been demonstrated.
- EU declaration of conformity is the manufacturer’s formal declaration that the device complies with the MDR and any other applicable EU legislation.
- Notified body certificate is issued by a designated notified body when the conformity assessment route requires third-party review.
- Technical documentation is the evidence file that supports conformity, including design information, risk management, verification, validation, clinical evaluation and post-market plans.
For a Class I non-sterile, non-measuring device that is not a reusable surgical instrument, the manufacturer may not receive a notified body CE certificate. That does not mean the product is free from MDR controls. The manufacturer still needs a defensible classification, complete technical documentation and a declaration of conformity before applying the CE mark. For Class IIa, Class IIb and Class III devices, notified body involvement is generally required.
When a notified body is required
The MDR uses risk classes to determine the conformity assessment route. Classification is therefore a commercial planning issue as well as a regulatory exercise. If the class is wrong, the manufacturer may choose an invalid route, prepare the wrong evidence, underestimate timelines or face questions from importers and distributors.
| Device situation | Typical CE route implication | Planning point |
|---|---|---|
| Class I device without sterile condition, measuring function or reusable surgical instrument status | Manufacturer self-declaration may be possible | Documentation and PMS obligations still apply |
| Class I sterile, Class I measuring or Class I reusable surgical instrument | Notified body involvement is required for the relevant limited aspects | Do not treat all Class I devices as simple self-certification |
| Class IIa device | Notified body conformity assessment is generally required | Plan for QMS review and technical documentation sampling |
| Class IIb device | Notified body conformity assessment is required, often with deeper technical review | Clinical evidence and risk management gaps can delay review |
| Class III device | Highest level of MDR scrutiny | Expect significant clinical, design and post-market evidence expectations |
Manufacturers outside the EU also need to plan for economic operator roles. A non-EU manufacturer generally needs an EU authorised representative before placing a device on the EU market. Importers and distributors have MDR verification duties, so they often ask for evidence of CE status, the declaration of conformity, certificates where applicable, UDI information and labelling controls.
Core evidence manufacturers need before CE certification
A practical CE plan should start with the device’s intended purpose, classification and applicable general safety and performance requirements. The MDR does not simply require a folder of test reports. It expects a coherent evidence package showing that the device is designed, manufactured, monitored and improved under a compliant system.
Quality management system
The MDR requires manufacturers to operate a quality management system covering regulatory strategy, design and manufacturing controls, supplier management, risk management, clinical evaluation, post-market surveillance, vigilance and corrective actions. ISO 13485 is commonly used as the quality-system framework in the medical device industry, but it should be mapped carefully against MDR Article 10 requirements rather than treated as an automatic substitute for legal compliance.
Technical documentation
Technical documentation should describe the device, variants, accessories, intended users, indications, design specifications, manufacturing processes and verification or validation data. It should also include risk management, benefit-risk analysis, labelling, instructions for use, UDI information and evidence addressing the general safety and performance requirements in Annex I of the MDR.
Clinical evaluation and post-market evidence
Clinical evaluation is not limited to a literature summary. It should connect the intended purpose, clinical benefits, known risks, state of the art, available clinical data and post-market follow-up plans. The level of evidence must be proportionate to the device class, claims, novelty and risk profile. After the device is placed on the market, post-market surveillance and vigilance obligations continue. CE marking is not the end of regulatory work.
Legacy device transition deadlines that still matter in 2026
The MDR transition has been amended because of notified body capacity constraints and concerns about device shortages. Regulation (EU) 2023/607 extended certain MDR transition periods, but the extension is conditional. As of September 2026, manufacturers should not read the extended deadlines as permission to postpone MDR work.
| Legacy device category under Regulation (EU) 2023/607 | Key market deadline | Important conditions |
|---|---|---|
| Class III devices and Class IIb implantable devices, except listed well-established technologies such as sutures, dental fillings and certain screws or plates | 31 December 2027 | Conditions include continued Directive compliance, no significant design or intended-purpose change, no unacceptable risk, MDR QMS in place by 26 May 2024, formal notified body application by 26 May 2024 and written agreement by 26 September 2024 |
| Other Class IIb devices, Class IIa devices, and Class I sterile or measuring devices with valid legacy status | 31 December 2028 | The same conditional framework applies |
| Devices that were self-declared under the MDD before 26 May 2021 but require notified body involvement under the MDR | 31 December 2028 | The device must fall within the transition provision and satisfy the conditions |
| Class III custom-made implantable devices covered by the special transition | 26 May 2026 | This date has already passed as of September 2026 |
The practical limitation is that the manufacturer needed to take action by dates that are now in the past. A company that did not lodge the required notified body application by 26 May 2024, or did not sign the required written agreement by 26 September 2024, cannot assume that the 2027 or 2028 deadline applies. It should obtain case-specific regulatory advice before continuing EU market activity.
Another important change is the removal of the earlier “sell-off” deadline. In simplified terms, devices lawfully placed on the market before or during the applicable transition period may continue to be made available or put into service. That does not remove vigilance, surveillance, documentation or safety obligations. See also: Implants.
EUDAMED and 2026 procedural changes
CE certification planning now also needs to account for EUDAMED, the European database for medical devices. The European Commission states that Commission Decision (EU) 2025/2371, published in the Official Journal on 27 November 2025, declared the first four EUDAMED modules functional. As a result, from 28 May 2026 the actor registration, UDI/device registration, notified bodies and certificates, and market surveillance modules are mandatory to use. The remaining post-market surveillance and vigilance module and the clinical investigation and performance studies module remain subject to their own rollout.
This matters because CE certification increasingly connects regulatory evidence, certificates, device identifiers and economic operator information in a more visible system. Manufacturers should align Basic UDI-DI decisions, certificate information, declarations and labelling data early, rather than treating EUDAMED as a final administrative upload.
A further 2026 development is Commission Implementing Regulation (EU) 2026/977, adopted on 4 May 2026 and published on 5 May 2026. It sets uniform quality management and procedural requirements for conformity assessment activities carried out by notified bodies under the MDR and IVDR. The practical effect is not that certification becomes automatic or easy. A more realistic expectation is greater standardisation of notified body procedures, which makes complete applications and well-organised evidence even more important.
Common planning risks before submitting a CE application
The most frequent CE delays are rarely caused by one missing form. They usually arise when the manufacturer’s intended purpose, claims, risk controls, clinical evidence and post-market strategy do not tell the same story.
- Classification is treated as an afterthought. Software, implantable devices, active therapeutic devices and devices with measuring functions can raise classification questions that change the entire pathway.
- Clinical claims exceed the evidence. Marketing language should be controlled against the intended purpose and available clinical data.
- Legacy assumptions are outdated. An MDD certificate or past CE mark does not automatically solve MDR evidence gaps.
- Supplier and subcontractor controls are incomplete. Notified bodies often look beyond the finished device file to manufacturing and critical supplier controls.
- Post-market surveillance is too generic. PMS plans should be device-specific and linked to known risks, expected clinical benefits, complaints, vigilance and post-market clinical follow-up where required.
- EUDAMED data is left too late. Registration information, UDI structures and certificate details should be reconciled before launch planning.
For a new MDR submission, a useful internal checkpoint is to ask whether a reviewer could understand the device, its intended users, benefits, risks, evidence and controls from the file alone. If the file depends on informal explanation to make sense, it is probably not ready for notified body review.
Frequently asked questions
Is CE certification mandatory for medical devices sold in the EU?
Yes. Medical devices generally need to comply with the applicable EU medical device legislation before being placed on the EU market, and compliant devices normally bear the CE marking. The route depends on the device type, class and conformity assessment procedure.
Can a manufacturer self-certify a medical device?
Some Class I devices can follow a manufacturer self-declaration route. However, Class I sterile devices, Class I devices with a measuring function and Class I reusable surgical instruments require notified body involvement for relevant aspects. Higher classes generally require notified body assessment.
How long does CE certification take?
There is no universal timeline. Timing depends on device class, completeness of the technical documentation, clinical evidence, quality system maturity, notified body availability, review findings and whether the device is novel or high risk. Manufacturers should plan in months, and for complex devices often longer.
Does an old MDD certificate remain valid under the MDR transition?
Some legacy certificates may remain valid under the conditional transition rules introduced by Regulation (EU) 2023/607. The answer depends on the device category, certificate history, whether the required 2024 application and written-agreement dates were met, and whether the device has avoided significant design or intended-purpose changes.
Is CE certification the same as FDA clearance?
No. CE marking under the EU MDR and FDA clearance or approval in the United States are different regulatory systems with different legal standards, procedures and evidence expectations. Evidence may overlap, but one authorization does not automatically replace the other.